Find a Pediatric Clinical Trial

Filter By:

Title	Investigator
A Non-Myeloablative Conditioning Regimen with Peri-Transplant Rituximab and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients with B cell Lymphoid Malignancies [Protocol 06-066]	Barker, Juliet, MBBS
A Phase I Study of 3F8 Antibody plus Granulocyte-Macrophage Colony-Stimulating Factor in High-Risk Neuroblastoma [Protocol 05-015]	Kushner, Brian, MD
A Phase I Study of Beta-Glucan and Rituximab in Children and Adolescents with Relapsed CD20-Positive Lymphoma or Leukemia or Post-Transplant Lymphoproliferative Disease [Protocol 03-095]	Modak, Shakeel, MD
A Phase I Study of CYT 107 in Recipients of HLA-Matched T Cell-Depleted Peripheral Blood Stem Cell or Bone Marrow Transplants [Protocol 07-127]	Van Den Brink, Marcel, MD, PhD
A Phase I Study of Clofarabine Plus Topotecan, Vinorelbine, Thiotepa, and Dexamethasone in Pediatric Patients with Relapsed or Refractory Acute Leukemia [Protocol 07-012]	Steinherz, Peter, MD
A Phase I Study of Intrathecal Radioimmunotherapy Using ¹³¹I-8H9 for Central Nervous System/Leptomeningeal Cancers [Protocol 03-133]	Kramer, Kim, MD
A Phase I Study of Oral Yeast Beta-glucan and Intravenous Anti-GD2 Monoclonal Antibody 3F8 Among Patients with Metastatic Neuroblastoma [Protocol 05-073]	Modak, Shakeel, MD
A Phase I Study of R1507 in Children and Adolescents with Advanced Solid Tumors [Protocol 07-142]	Trippett, Tanya, MD
A Phase I Study of SGN-33 (Lintuzumab) in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome [Protocol 05-132]	Jurcic, Joseph, MD
A Phase I Study of WT1-Sensitized T cells for Residual or Relapsed Leukemia after Allogeneic Hematopoietic Progenitor Cell Transplantation [Protocol 07-055]	O'Reilly, Richard, MD
A Phase I Study of an Ethanol-Lock Strategy to Prevent Central Venous Catheter Infections Among Patients with High-Risk Neuroblastoma [Protocol 07-047]	Kayton, Mark, MD
A Phase I Study of the Monoclonal Antibody HGS-ETR2 (Lexatumumab) in Patients with Refractory Pediatric Solid Tumors [Protocol 07-071]	Merchant, Melinda, MD, PhD
A Phase I Trial of Sequential Paclitaxel/Ifosfamide and Dose-Intensive Paclitaxel, Carboplatin, and Dose-Escalated Ifosfamide with Stem Cell Support in Cisplatin- Resistant Germ Cell Tumor Patients [Protocol 06-077]	Motzer, Robert, MD
A Phase I/II Study of Allogeneic Bone Marrow Transplantation for the Treatment of Genetic Disorders of Erythropoiesis [Protocol 94-005]	Boulad, Farid, MD
A Phase I/II Study of Clofarabine in Combination with Etoposide and Cyclophosphamide in Pediatric Patients with Refractory or Relapsed Acute Leukemia [Protocol 07-039]	Steinherz, Peter, MD
A Phase I/II Study of Clofarabine in Patients with Relapsed T-cell and NK-Cell Lymphomas [Protocol 06-065]	Horwitz, Steven, MD
A Phase I/II Study of Temsirolimus (CCI-779) in Children with Relapsed or Refractory Solid Tumors (Part 2) [Protocol 07-060]	Dunkel, Ira, MD
A Phase I/II Study of the Toxic and Therapeutic Effects of T Cells in the Treatment of Epstein Barr Virus-Associated Lymphoproliferative Disorders [Protocol 95-024]	O'Reilly, Richard, MD
A Phase I/II Trial of Clofarabine, Melphalan, and Thiotepa Followed by an Allogeneic Stem Cell Transplant for the Treatment of High-Risk and/or Advanced Hematologic Malignancies [Protocol 06-125]	Boulad, Farid, MD
A Phase II Pilot Trial of Hematopoietic Stem Cell Transplantation with Total Body Irradiation, Cyclophosphamide & Fludarabine to Treat Patients with Fanconi Anemia Lacking a Genotypically Identical Donor [Protocol 01-062]	Boulad, Farid, MD
A Phase II Study of Anti-GD2 Antibody 3F8 and GM-CSF for High-Risk Neuroblastoma [Protocol 03-077]	Kushner, Brian, MD
A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas [Protocol 07-049]	Dunkel, Ira, MD
A Phase II Study of Intrathecal I¹³¹-3F8 in Patients with GD2-Expressing Central Nervous System and Leptomeningeal Neoplasms [Protocol 05-122]	Kramer, Kim, MD
A Phase II Study of Motexafin-Gadolinium and Involved Field Radiation Therapy for Intrinsic Pontine Glioma of Childhood [Protocol 07-140]	Dunkel, Ira, MD
A Phase II Study of Pemetrexed in Children with Recurrent Malignancies [Protocol 07-179]	Trippett, Tanya, MD
A Phase II Study of Peri-transplant Palifermin followed by an Allogeneic T-Cell-Depleted Stem Cell Transplant in Patients with Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Evolved from MDS [Protocol 08-008]	Castro-Malaspina, Hugo, MD
A Phase II Study of Sunitinib in Patients with Refractory or Relapsed Germ Cell Tumors [Protocol 07-004]	Motzer, Robert, MD
A Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants after a Myeloablative Preparative Regimen for Adult Patients with Lymphohematopoietic Disorders [Protocol 01-070]	Jakubowski, Ann, MD, PhD
A Phase II Trial of HLA Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Leukemia Following Allogeneic Hematopoietic Stem Cell Transplant [Protocol 07-035]	Hsu, Katharine, MD, PhD
A Phase II Trial of Intravenous Myeloablative Chemotherapy Followed by an Allogeneic Hematopoietic Stem Cell Transplant from a Matched Relative to Treat High-Risk Ewing's Sarcoma Family Tumors [Protocol 05-059]	Prockop, Susan, MD
A Phase II Trial of Irinotecan plus Carboplatin, and Irinotecan Maintenance Therapy Integrated into the Upfront Therapy of Newly Diagnosed Patients with Intermediate- and High-Risk Rhabdomyosarcoma [Protocol 03-099]	Wexler, Leonard, MD
A Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcomas [Protocol 07-104]	Maki, Robert, MD
A Phase II Trial of R1507 for People with Recurrent Sarcoma [Protocol 07-166]	Maki, Robert, MD
A Phase II Trial of T Cell Depleted Peripheral Blood Stem Cell Transplantation to Treat Patients with AML in First or Second Complete Remission [Protocol 06-005]	O'Reilly, Richard, MD
A Phase III Study Assessing Carboplatin and/or Isotretinoin plus Radiation in Patients with Supratentorial Primitive Neuroectodermal Tumor or High-Risk Medulloblastoma [Protocol 07-174]	Gilheeney, Stephen, MD
A Phase III Study for the Treatment of Children and Adolescents with Newly Diagnosed Low-Risk Hodgkin's Lymphoma [Protocol 07-008]	Trippett, Tanya, MD
A Phase III Study of Defibrotide for the Treatment of Severe Hepatic Veno-Occlusive Disease in Hematopoietic Stem Cell Transplant Patients [Protocol 06-127]	Kernan, Nancy, MD
A Phase III Study of Intensive Induction Chemotherapy with or without Methotrexate Followed by Consolidation Therapy with Stem Cell Rescue in Young Children Newly Diagnosed with Supratentorial PNET or High-Risk Medulloblastoma [Protocol 07-170]	Gilheeney, Stephen, MD
A Phase Ia/Ib Study of a DNA Vaccine in Patients with Stage IIB-IV Malignant Melanoma [Protocol 07-003]	Wolchok, Jedd, MD, PhD
A Pilot Phase II Study of Targeted Radiotherapy with ¹³¹I-MIBG and Arsenic Trioxide in Patients with Resistant Neuroblastoma or Malignant Chromaffin Cell Tumors [Protocol 04-148]	Modak, Shakeel, MD
A Randomized Controlled Trial of Family-Focused Grief Therapy in Palliative Care and Bereavement [Protocol 05-120]	Kissane, David, MD
A Study of Salvage Chemotherapy Followed by Allogeneic Hematopoietic Stem Cell Transplant for the Treatment of High-Risk or Relapsed Hodgkin's Lymphoma [Protocol 07-147]	Perales, Miguel-Angel, MD
ALTE03N1: Key Adverse Events Following Childhood Cancer [Protocol 05-070]	Sklar, Charles, MD
Classification of Acute Lymphoblastic Leukemia [Protocol 06-023]	Shukla, Neerav, MD
Combination of Targeted I¹³¹-3F8-Mediated Radioimmunotherapy and Bevacizumab in Patients with Relapsed or Refractory Neuroblastoma: A Phase I Study [Protocol 06-072]	Modak, Shakeel, MD
Cross-Sectional Study of Psychosexual Impact of Cancer-Related Infertility in Women: Third Party Reproductive Assistance [Protocol 06-110]	Carter, Jeanne, PhD
Cyclophosphamide, Fludarabine, and Total Body Irradiation Followed by the Transplantation of Unrelated Double-Unit Donor Umbilical Cord Blood Grafts for Patients with Hematological Malignancy [Protocol 06-014]	Barker, Juliet, MBBS
Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation from HLA-Compatible Unrelated Donors in Severe Aplastic Anemia [Protocol 06-056]	Castro-Malaspina, Hugo, MD
GLIOGENE: Genetic Epidemiology of Glioma International Consortium [Protocol 07-137]	Bernstein, Jonine, PhD
Genetic Variability as a Determinant of Chemotherapy Toxicity and Response in Pediatric Cancer and Bone Marrow Transplantation Patients [Protocol 03-123]	Meyers, Paul, MD
Health-Related Outcomes for Hodgkin's Disease Survivors [Protocol 06-140]	Trippett, Tanya, MD
Injection of Melanoma Patients with Mouse TRYP2 DNA: A Phase I Trial to Assess Safety and Immune Response [Protocol 06-052]	Wolchok, Jedd, MD, PhD
Liposomal Muramyl Tripeptide Phosphatidyl Ethanolamine (L-MTP-PE): Compassionate Access for High-Risk Osteosarcoma [Protocol 08-021]	Meyers, Paul, MD
Molecular Characterization of Neuroblastic Tumors and Clinical Outcome [Protocol 00-109]	Cheung, Nai-Kong, MD, PhD
Participation in the National Marrow Donor Program Registry [Protocol 90-091]	Kernan, Nancy, MD
Partnership for Health: A Web-Based Smoking Intervention for Cancer Survivors [Protocol 05-093]	Ford, Jennifer, PhD
Phase I Study of MDX-1401 in Patients with CD30-Positive Refractory/Relapsed Hodgkin's Lymphoma [Protocol 07-169]	Horwitz, Steven, MD
Phase II Prospective Clinical Trial of Vaccine Responses in Childhood Survivors of Cancer Who Had Chemotherapy [Protocol 07-088]	Small, Trudy, MD
Phase II Study of Nimotuzumab (TheraCIM^®) in Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma [Protocol 08-034]	Trippett, Tanya, MD
Pilot Study of Molecular Imaging Using Positron Emission Tomography (PET) to Determine Protein and Gene Expression Signatures of Colonic Polyps [Protocol 07-114]	Gollub, Marc, MD
Pilot Trial to Determine Toxicity and Antibody Responses with a Vaccine Containing GD2 Lactone and GD3 Lactone in Patients with Disease-Free Stage III or IV Melanoma [Protocol 06-086]	Chapman, Paul, MD
Radioimmunotherapy, Reduced-Dose External Beam Craniospinal Radiation Therapy with IMRT Boost & Chemotherapy for Patients with Standard-Risk Medulloblastoma [Protocol 02-088]	Dunkel, Ira, MD
Radiotherapy Alone versus Chemotherapy Followed by Response-Based Radiotherapy for Newly Diagnosed Primary CNS Germinoma [Protocol 07-167]	Dunkel, Ira, MD
Retinoblastoma Survivor Study: Assessment of General Health and Quality of Life [Protocol 08-019]	Dunkel, Ira, MD
Vincristine, Dactinomycin, and Lower Doses of Cyclophosphamide in Patients with Newly Diagnosed Low-Risk Embryonal/Botryoid Rhabdomyosarcoma [Protocol 05-032]	Wexler, Leonard, MD

Site Map \| Index	Legal Disclaimer \| Privacy Practices \| Public Notices

©2008 Memorial Sloan-Kettering Cancer Center. 212-639-2000 1275 York Avenue New York, NY 10065.	PublicAffairs@mskcc.org